AXGN
Axogen, Inc.
NASDAQ · Healthcare · Medical - Devices · US
$44.23
−2.33%Sep 10, 2026, 10:01 UTC
Axogen, Inc. announced the pricing of an underwritten public offering of 4,910,000 shares of its common stock at $42.50 per share, expecting gross proceeds of approximately $208.7 million.
Source:Sep 10, 2026, 10:00 UTC
Axogen entered into a definitive agreement to acquire BioCircuit Technologies, adding the FDA-approved NerveTape device for sutureless peripheral nerve repair.
Aug 3, 2026, 06:37 UTC
Axogen received FDA biologic approval for Avance, granting 12 years of exclusivity.
Source:Jul 29, 2026, 11:10 UTC
Trace Biosciences announces a strategic investment from Axogen to advance clinical development of its Nerve Trace nerve-specific imaging technology.
Source:Jul 29, 2026, 11:05 UTC
Axogen, Inc. reported its financial results for the second quarter of 2026.